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Summary. The rationale, trial design, and statistical aspects 
of  QUIET, the QUinapril Ischemic Event Trial, are de- 
scribed. QUIET is a prospective, double-blind placebo- 
controlled study that will  assess the ability of  the angioten- 
sin-converting enzyme (ACE) inhibitor quinapril to reduce 
the rate of  cardiac ischemic events and to slow or prevent the 
development of  coronary artery atherosclerosis as assessed 
by serial angiography in a normolipidemic population with- 
out left ventricular dysfunction.  The study began in Septem- 
ber 1991 and has completed recruitment with 1740 patients 
across 38 centers (28 U.S., 4 Canada, 6 Europe) by the end of  
1992. Patients  are randomized to 20 mg of quinapril or pla- 
cebo once daily and continue in the study for 3 years. Study 
completion is projected for 1995. 
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In  the search for the causes and cures for coronary 
artery disease, studies of interventions such as diet 
[1], drug therapy [2-4], and surgery [5,6] have re- 
ported promising trends in hyperlipidemic populations 
based on assessments of plasma lipid and lipoprotein 
changes, and angiographic evidence of lesion regres- 
sion or lack of progression. However, because not all 
patients with coronary artery disease have abnormal 
lipid values, investigations are under way to delineate 
other pathophysiological mechanisms and treatment 
approaches. 
In particular, in populations with confirmed core- 
nary artery disease but without the primary diagnosis 
of hyperlipidemia, the calcium channel antagonists 
nifedipine and nicardipine have been shown to inhibit 
new lesion progression, albeit with adverse trends in 
clinical sequelae [7,8]. 
Preclinical work with angiotensin-converting en- 
zyme (ACE) inhibitors has prompted interest in the 
possible effects on coronary artery disease progres- 
sion. Through a summation of angiotensin-blocking 
and bradykinin-potentiating effects, these drugs are 
thought to preserve endothelial integrity and to pre- 
vent lipid accumulation as well as to inhibit cellular 
growth and proliferation of the intimal lining. Other 
potential beneficial actions of ACE inhibitors include 
the antagonism of macrophage function [9] and migra- 
tion [10,11], and inhibition of sympathetic nervous 
system activity [12]. In preclinical studies, various 
ACE inhibitors reduced neointimal thickening in re- 
sponse to intimal injury of the rat carotid [13] and 
prevented atherosclerotic progression in both the rab- 
bit [10] and monkey [14]. 
Among clinical investigations of ACE inhibitors as 
antiatherosclerotic agents to date is the Multicenter 
European Research Trial With Cilazapril After An- 
gioplasty to Prevent Transluminal Coronary Obstruc- 
tion and Restenosis (MERCATOR) [15]. In this study 
the ACE inhibitor cilazapril had no effect on resteno- 
sis as assessed by angiography, but in the active treat- 
ment group the data did show an apparent trend to- 
ward fewer clinical cardiac endpoints, such as death, 
myocardial infarction, and coronary revascularization 
(Figure 1) [16]. 
A lower incidence of cardiovascular endpoints was 
also apparent with enalapril in the Studies of Left 
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Fig. 1. Percent reduction in ischemic events vs. placebo for MERCATOR [16], SOLVD [17,18], and SAVE [19]. Mean treatment 
times: SOLVD, 41.4 months; MERCATOR, 12 months; SAVE, 7 months. 
Ventricular Dysfunction (SOLVD) [17,18] and capto- 
pril in the recent postmyocardial infarction trial, 
SAVE [19] (Figure 1). Like MERCATOR, however, 
these antiischemic effects were observational findings 
and, until now, have not been the subject of formal 
hypothesis testing. 
The QUinapril Ischemic Event Trial (QUIET), 
therefore, is the first study to investigate the long- 
term effects of ACE inhibition in a large, homoge- 
neous population with normal low-density lipoprotein 
(LDL) cholesterol and left ventricular function, but 
with documented coronary artery disease requiring 
intervention in the form of angioplasty or atherec- 
tomy. In light of recent data supporting the existence 
of an autocrine-paracrine (tissue) renin angiotensin 
system subserving largely chronic adaptive cardiovas- 
cular changes [20], the ACE inhibitor quinapril was 
selected based on its documented potent binding to 
the converting enzyme in both arterial and cardiac 
tissue [21,22]. This prospective, double-blind, pla- 
cebo-controlled trial will evaluate the ability of quin- 
april to reduce the rate of cardiac ischemic events and 
to slow or prevent the development of coronary artery 
atherosclerosis as assessed by serial angiography. 
T r i a l  D e s i g n  
Patient population 
QUIET is a double-blind, randomized, parallel-group, 
placebo-controlled study of 1700 men and women, 75 
years of age or less, who have undergone successful 
single- or double-vessel angioplasty or atherectomy 
(Simpson device or excimer laser) within 72 hours 
prior to randomization. For purposes of this study, 
successful angioplasty is defined as a >20% change in 
luminal diameter narrowing and a residual diameter 
of -<50% stenosis in a patient without associated myo- 
cardial infarction or the need for acute coronary ar- 
tery bypass grafting (CABG). Patients must also have 
at least one main coronary artery that has never been 
subjected to invasive intervention. 
Patients are required to have LDL cholesterol lev- 
els -<4.27 mmol/1 (165 mg/dl) without lipid regulating 
drugs and to be normotensive [systolic blood pressure 
(SBP) between 100 and 160 mmHg; diastolic blood 
pressure (DBP) -<95 mmHg] at baseline. Patients 
with controlled hypertension may enter providing 
they are not receiving excluded antihypertensive 
medications. The left ventricular ejection fractions 
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must be ->40% by multiple-gated angiography 
(MUGA), echocardiography, or ventriculography at 
the time of initial angiography. 
Not eligible for the study are patients who undergo 
any other intervention at the time of angioplasty or 
atherectomy, those with prior CABG, any other inter- 
vention within the 3 months preceding randomization, 
or myocardial infarction within the previous 7 days. 
Excluded medications at the time of randomization 
include lipid-lowering agents and ACE inhibitors. 
After randomization, calcium channel antagonists are 
also excluded. Patients may not have other diseases, 
including Type I diabetes mellitus, renal disease, liver 
disease, or hepatic dysfunction by standard laboratory 
screen; or laboratory abnormalities that  might inter- 
fere with assessing results. Women may not be preg- 
nant or lactating, and those of child-bearing potential 
must use a reliable birth control method throughout 
the trial. 
The study is being carried out in accordance with 
the Declaration of Helsinki and patients may with- 
draw voluntarily at any stage. Patients are thor- 
oughly informed of the details of the study, have the 
opportunity to ask questions, and must sign and have 
witnessed a writ ten informed consent s tatement be- 
fore randomization. At each site, the institutional re- 
view board or ethical review committee must review 
and approve the protocol and consent form. 
T r e a t m e n t  
Patients are screened for eligibility at the time of an- 
gioplasty or atherectomy, and eligible patients are 
randomized to quinapril or placebo within 12-72 hours 
in a double-blind fashion according to a randomization 
code provided by the sponsor. The 12- to 72-hour win- 
dow ensures early exposure to quinapril but avoids 
administering the drug immediately after the proce- 
dure during a potentially unstable period. To minimize 
the chance of first-dose hypotension, patients receive 
10 mg of quinapril the first day and a daily dose of 
20 mg thereafter.  Patients receive either 20 mg of 
quinapril or placebo once daily for a minimum of 3 
years. 
Patients are stratified by center as well as by se- 
veri ty of disease, that  is, single- vs. multiple-vessel 
disease. Single-vessel disease is a lesion or' lesions 
with ->50% luminal diameter narrowing throughout 
the length of only one of the left anterior descending, 
left circumflex, or right coronary artery,  or in a major 
branch or branches of one of those vessels. Multiple- 
vessel disease is lesions with >-50% luminal diameter 
narrowing in two or more of the major coronary ar- 
teries. 
Patients are seen at 2-month intervals for the first 
two visits and then at 4-month intervals for the re- 
mainder of the study (Table 1). At their final visit, 
30% of enrolled patients who complete the 3-year dou- 
ble-blind period will be randomly selected to undergo 
a repeat  coronary angiogram under the same condi- 
tions and specifications as the baseline angiogram. If  
patients require an interim angiogram for whatever  
reason, every effort will be made to have it conform 
to the same specifications as the baseline angiogram. 
Those patients requiring an interim angiogram for a 
clinical endpoint during months 30-36 will not un- 
dergo a final angiogram at the end of the study, nor 
will those who require coronary bypass at any point 
during the study. 
The double-blind t rea tment  continues for a mini- 
mum of 3 years or until a prespecified number of pa- 
tients experience at least one cardiac ischemic end- 
Table 1. Timetable of clinic visits and procedures 
Visit Scr/D1 b D2 D3 D4 D5 D6 D7 D8 D9 D10 Dll 
Study Month 0 0.5 2 4 8 12 16 20 24 28 32 36 
Angiography X 
Clinic visit X 
Medical history X 
Physical exam X 
Patient contact a 
Full clinical 
laboratory X 
Lipid measurements X 
ECG X 
Medication dispensing X e 
Reserve samples d X 
Insulin sensitivity e X 
X 
X X X X X X X X X X 
X X X 
X X X X X X X 
X X X 
X X 
X X X X X X X X X 
X X 
X X 
aFollow-up phone call by coordinator, 2-3 weeks after randomization. 
bScreening and first double-blind visit (D1) may be the same day. 
°Qualifying patients. 
dScr = screening visit; D = double-blind visits. 
eNorth American centers only. 
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point. Patients who experience nonfatal endpoints will 
continue to receive quinapril or placebo according to 
the randomization. 
Efficacy parameters 
Cardiac ischemic endpoints. The efficacy evaluations 
of drug therapy are based primarily on the time to 
the first cardiac ischemic event, as determined below, 
during the double-blind period. By agreement with 
the Cardio-Renal Division of the Food and Drug Ad- 
ministration, cardiac ischemic events are reported as 
primary study endpoints rather than as adverse 
events. 
An Ischemic Event  Endpoint Committee consisting 
of five physicians involved in the trial reviews all 
deaths, myocardial infarctions and cases of angina or 
chest pain requiring hospitalization to decide whether 
the data support the diagnosis of a clinical ischemic 
event. For  statistical and analytical purposes, isch- 
emic endpoints are defined as follows: 
• Sudden cardiac death--death from electrocardio- 
graphically (ECG)-proven venricular fibrillation or 
other fatal arrhythmia with no, or within I hour of, 
cardiac symptomatology; witnessed death within 
1 hour of cardiac sympatomatology; unwitnessed 
death due to acute cardiac insult as confirmed by 
autopsy 
• Death within 28 days of proven myocardial infarc- 
t i on -de f ined  as changes in one or more of three 
parameters: symptomatology, enzyme elevation, 
and ECG changes (Table 2) 
• Nonfatal myocardial infarction--as defined in Ta- 
ble 2 
• Coronary artery bypass grafting (CABG) (Patients 
with this endpoint can continue the study but will 
not be considered for the final angiogram.) 
• Intervention--such as angioplasty, atherectomy, 
laser ablation, stenting, or any newly introduced 
invasive procedure for the management of coronary 
artery disease. 
• Angina requiring hospitalization 
Angiography methods. Cardiac catheterization is 
performed by either the femoral or brachial approach 
with standard premedication, 5000 units of heparin 
through the arterial sheath, and nitroglycerin to stan- 
dardize coronary vasomotor tone. Optimal views with 
minimum overlap and foreshortening are sought for 
each of the major coronary artery segments described 
below. The cine field is carefully centered to include 
the distal end of the catheter for use as a scaling factor 
in quantitative analysis. 
During the baseline angiogram, the degree of axial 
(RAO/LAO) rotation and cranial/caudal angulation, 
and the types, manufacturers, and sizes of catheters 
for each injection are documented on worksheets. 
After the patient is discharged from the hospital, 
catheters, cine film, and a copy of the worksheet are 
express mailed to the core laboratory. 
Angiograms are analyzed as the cine films become 
available. The referring study center is informed of 
which angiographic projections from the initial proce- 
Table 2. Definite myocardial infarction criteria* 
Electrocardiography 
Symptomatology New New New Other or 
abnormal T wave ST segment no 
Category Typical Atypical None Q wave inversion changes  changes 
Cardiac enzymes 
CK > 2N 
LDH > 1.5N Other or 
CK-MB (LDH1 > LDH 2) no 
>5% & SGPT > 3N changes 
la X < ......................... ANY .......................... > 
b X X 
c X X X 
d X X X 
2a X X X 
b X X X 
c X X X 
d X X X 
e X X X 
3a X X X 
b X X X 
c X X X 
d X X X 
X 
< ................... ANY ................... > 
* The table is a modification of criteria used in CASS [25]. 
CK = creatine kinase; CK-MB = creatine kinase MB isoenzyme; LDH = lactate dehydrogenase; LDH 1 and LDHe = subfractions; SGPT = 
serum glutamic-pyruvic transaminase; N = normal. 
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Left main coronary artery (LMCA) - #11 
Left anterior descending artery (LAD) divided as follows: 
Prox LAD - proximal segment from division of LM to first 
diagonal - # 12 
Mid LAD - middle segment from first diagonal to second 
diagonal - # 13 
Dist LAD - distal segment distal to second diagonal - #14 
1st diag - first diagonal branch of LAD - #15 
2nd diag - second diagonal branch of LAD - #16 
Left circumflex artery (LCX) divided as follows: 
Prox CX - proximal segment from division of LM to first obtuse 
marginal branch - #18 
Dist CX - distal segment from the first to the second obtuse 
marginal branch- #19 
1st OB Marg - first left obtuse marginal branch - #20 
2nd OB Marg - Second left obtuse marginal branch - #21 
1st LPL or RPL - first left or right posterolateral 
branch - #24 
Right coronary artery (RCA) divided as follows: 
Prox RCA - proximal segment from origin to right 
ventricular branch - #1 
Mid RCA - middle segment from right ventricular branch to 
acute marginal branch - #2 
Dist RCA - distal segment distal to acute marginal 
branch - #3 
RPDA - right posterior descending branch - #4 
Fig. 2. Major coronary artery segments from the Coronary Artery Surgery Study [26]. 
dure are selected for analysis, so they can be dupli- 
cated on follow-up. The computerized quantitative 
coronary analysis system [23,24] has the option of us- 
ing the cine film digitizers, so the baseline angiogram 
can be reanalyzed with the follow-up angiogram for 
optimal evaluation of serial changes. This assures that 
segments are accurately matched for anatomic land- 
marks, length, and position in the cardiac cycle. The 
edge-detection function sums the scaled first and sec- 
ond derivatives, and longitudinal edge detection is 
performed by a "least cost" method, with the possibil- 
ity of operator editing. A center line is constructed 
and the diameter is computed as the distance between 
the edges perpendicular to the center line. Since cath- 
eters of equal outside diameters but of different ma- 
terials or manufacturers have significantly different 
radiographically calculated diameters, the analysis 
program includes a table to calculate a catheter- 
specific calibration factor [25]. 
A qualified physician selects and records the views 
and segments for analysis, choosing the cardiac cycle 
providing the best opacification and end-diastolic 
frame for each view. Technicians fully trained to use 
the quantitative angiographic analysis system per- 
form the analysis. 
All evaluable segments ->1.5 mm diameter and >5 
mm length are analyzed (Figure 2) [26]. At least one 
boundary (proximal or distal) for each segment is re- 
lated to a precise anatomic landmark, usually a branch 
origin, and the length of the segment is recorded to 
aid in precise replication of segments analyzed in fol- 
low-up studies. The angiographic analysis from each 
selected frame is printed out to guide the selection of 
identical segments for follow-up studies. For all seg- 
ments, borders of stenotic lesions >20% are demar- 
cated, and a normal reference segment is identified 
when possible. If stenosis is present, the view show- 
ing the severest degree of stenosis is selected for 
analysis. 
Because of the normal variability of coronary ar- 
tery anatomy, the precise demarcation and number of 
segments analyzed vary from patient to patient. Of 
the potential segments typically available, evaluation 
of at least 10 will be attempted (Figure 2). 
Safetg monitoring 
An independent Safety Data Monitoring Committee, 
comprising three physicians and a statistician not in- 
volved in conducting the trial, continuously monitors 
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all ischemic events and medically serious adverse 
events. The committee members have sole access to 
unblinded data and will not communicate any results 
to the trial sponsor unless they are recommending 
that the trial be discontinued. The committee meets 
every 6 months throughout the trial or more fre- 
quently if the chairperson deems it necessary. 
The committee will inform the sponsor when the 
placebo group is approaching an overall cardiac isch- 
emic event rate of 36% and a "late"-events-only rate 
of 16% (ischemic events occurring after the first 6 
months and not considered to be restenosis) so that 
these levels would be likely to be reached by the next 
scheduled committee meeting. After notification, the 
sponsor will decide whether to stop or continue the 
trial. This process may be repeated at each subse- 
quent committee meeting. If these event-rate criteria 
are not reached after 3 years, the committee may rec- 
ommend continuing the trial for at least 6 additional 
months. If a formal plan of interim analyses becomes 
necessary, or if the trial is stopped early due to a 
safety concern, the Lan-DeMets procedures will be 
applied [27]. 
All patients undergo physical examinations at 
screening and yearly thereafter.  Blood pressure and 
heart rate are recorded at each clinic visit. For  pa- 
tients developing hypotension, medications other than 
the study drug are adjusted first; if necessary, the 
dose of quinapril is halved. Any patient with persis- 
tent hypotension will be withdrawn from double-blind 
therapy. 
Adverse events will be recorded at each clinic visit 
or as they are reported to the investigator. Abnormal- 
ities in clinical laboratory determinations or ECGs not 
related to an ischemic endpoint are treated as adverse 
events. 
Patients whose LDL cholesterol level exceeds 5.95 
mmol/1 (230 mg/dl) on any one determination or re- 
mains persistently above 5.17 mmol/1 (200 mg/dl) on 
two successive visits despite dietary counselling may 
receive open-label, lipid-lowering medication and have 
LDL cholesterol determinations at each visit thereaf- 
ter. Regardless of therapy, these patients remain in 
the study for intent-to-treat purposes. 
Statistical methods 
Sample size determination. By extrapolation from 
published data [28-32], we anticipate that 20% of pa- 
tients who receive placebo will experience restenosis 
based on clinical symptomatology within 6 months of 
the intervention. The assumed rate of cardiac events 
during months 6-36 is 8.4% for patients with single- 
vessel disease and 24.0% for those with multiple- 
vessel disease (Figure 3) [31-33]. Because of this wide 
variation in the expected incidence of cardiac ischemic 
events during months 6-36 depending on disease se- 
verity, the t reatment  groups are stratified by this pa- 
rameter to ensure similar proportions in the drug and 
placebo treatment groups. Given single- and multiple- 
vessel disease in a 50/50 proportion, the expected inci- 
dence of cardiac ischemic events during months 6-36 
is 16.2% (8.4% + 24.0% ÷ 2). Therefore, we expect 
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that 36% (20% + 16%) of the placebo-treated patients 
will have at least one cardiac ischemic endpoint, in- 
cluding restenosis, over a 3-year period. To detect a 
25% reduction of endpoints in the quinapril-treated 
group (i.e., 27% of quinapril-treated patients with at 
least one cardiac ischemic event, including restenosis) 
with a log-rank test  at a two-sided significance level 
of 5% with 95% power requires 750 patients per treat- 
ment group. 
Sample size and power estimates were also calcu- 
lated for the two phases of ischemic events likely to 
be encountered in this trial. To detect a 25% reduction 
in incidence of clinical restenosis in the quinapril- 
treated group within the first 6 months of double-blind 
treatment using a chi-square test  of proportions at 
a one-sided 5% significance level, 1700 patients will 
provide approximately 80% power. To detect a 25% 
reduction in ischemic events during months 6-36 in 
the quinapril-treated group with a log-rank test at a 
two-sided significance level of 5%, 1700 patients will 
provide >80% power. 
For the angiographic analyses the incidence of pro- 
gression in the placebo treatment group was assumed 
to be 0.45 (45% of patients in the placebo treatment 
group demonstrating "progression"--however de- 
f ined--over a 3-year period) [3,4,7,8,34-40]. Thus, for 
a test with 80% power at a two-sided 5% significance 
level to detect a 30% reduction (to 0.315) in the quin- 
april t reatment group, 203 patients are required per 
treatment group. Assuming a 15% dropout rate, 240 
patients per t reatment group are needed. 
Efficacy analgses. The time to the first cardiac isch- 
emic event will be analyzed by a two-sided log-rank 
test with a 5% level of significance. Logistic regres- 
sion and Cox Proportional Hazards models will be 
used to determine the relative risk (odds ratio and 
hazard ratio) of cardiac ischemic events in the treat- 
ment groups and the 95% confidence interval for the 
odds ratio and hazard ratio, as well as to assess rela- 
tionships between various risk factors, as determined 
before breaking the blind, and both outcome and time 
to event. 
The primary analysis Will be based on the intent-to- 
treat  population to include all patients randomized to 
treatment whether or not they are active in the trial 
at the time of any cardiac ischemic event. Analyses 
will be done across all study centers, continents, and 
randomization strata, without interaction terms. Sup- 
plemental analyses will consider both the severity of 
individual endpoints and the possibility of multiple 
endpoints. Survival analysis will be done on the time 
to the most serious event ra ther  than the first event. 
This ranks severity of endpoints as follows in as- 
cending order of severity: angina requiring hospital- 
ization, invasive intervention, CABG, nonfatal myo- 
cardial infarction, fatal myocardial infarction, and 
sudden cardiac death. 
Fur ther  analyses will focus on specific endpoints, 
individually and together, such as myocardial in- 
farction and subsequent sudden death. Such a group- 
ing of endpoints will allow easier analysis of the data 
within a competing risks framework. The effects of 
treatment on specific endpoints and the relationship 
among them will be examined. 
The interaction of t reatment  group with the strati- 
fication variables will be analyzed at the 5% signifi- 
cance level. If any interaction is significant, single- 
factor, pairwise comparisons will be done at the 5% 
significance level, two-tailed. 
The incidence of early events within the first 6 
months and cardiac ischemic events between months 
6 and 36 will be analyzed as above, using ~,~urvival 
analysis methods. 
Similar analyses will be done for an evaluable pa- 
tient population, defined as those who satisfy criteria 
for compliance to study medication and adherence to 
major inclusion/exclusion criteria (per protocol pop- 
ulation). Evaluability will be determined prior to 
breaking the blind. 
Angiographic analgses. The angiographic progres- 
sion of coronary atherosclerosis will be determined 
from changes in four measurements: 
• minimum lumen diameter 
• percent stenosis 
• mean segment diameter 
° appearance of new lesions 
For each patient, the mean of each of these mea- 
surements for all evaluable segments will be calcu- 
lated to provide indices of change from the baseline. 
At present, the mean segment diameter index (MSDI) 
is considered to be the most appropriate efficacy pa- 
rameter for statistical analysis of angiographic re- 
sults. 
Because the likely extent of MSDI change in 3 
years is unknown, "progression" has been defined on 
the basis of empirical rules, applying the following 
procedures to blinded clinical data. Without breaking 
the blind, the following three items will be performed 
as necessary: 
1. The median change from baseline in MSDI will be 
computed based on all patients completing the 3- 
year, double-blind treatment period, regardless of 
t reatment group. This median will be used to con- 
struct two categorical groups--one consisting of 
patients with disease severity > median and the 
other of patients with disease severity -< median. 
2. During the study period, continuing research may 
identify a more sensitive parameter  that indicates 
changes in coronary ar tery  atherosclerosis caused 
by various treatments.  If possible, the computation 
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described above will be performed on this newly 
designated parameter. 
3. When the most sensitive measure of treatment 
change is identified, the construction of the cate- 
gorical groups may be adjusted in order to further 
define disease "progression." This definition will be 
used to classify a patient as a progressor (disease 
severity > median) or nonprogressor (disease se- 
verity -< median). 
Secondary angiographic parameters will include 
measures derived from baseline and final angiograms 
for each patient. Mean values for the angiographic 
change in each treatment group will be compared, 
generally by analysis of variance (ANOVA), including 
the center and disease severity stratification indicator 
in the model as covariates. If statistical considerations 
warrant, appropriate alternatives to ANOVA (non- 
parametric methods) will be applied. Other covari- 
ares, specified before breaking the blind, will be con- 
sidered in exploratory analyses. Secondarily, the 
percentage of patients experiencing specified types of 
changes will be explored, for example, the percentage 
with disease progression by treatment group, with 
center and stratification factor as blocking factors. 
Percentages between groups will be compared by lo- 
gistic regression with center and stratification as 
blocking factors. 
Discuss ion  
In designing any major intervention study, one of the 
challenges is to define an appropriate study popula- 
tion. Too narrow a population may be difficult to re- 
cruit and, ultimately, may produce findings not clearly 
applicable to the clinical situation, while too broad a 
population may introduce confounding variables and 
hinder interpretation of results. QUIET targets a ho- 
mogeneous population with coronary artery disease, 
defined as patients undergoing angioplasty or atherec- 
tomy, common interventions with reported similari- 
ties in restenosis rates [41]. It should be recognized 
that the study is not primarily a restenosis trial; reste- 
nosis is, however, one of several endpoints. 
The selection of normotensive patients, including 
those with hypertension controlled at baseline, per- 
mrs a placebo control, reducing the likelihood of con- 
cluding that any beneficial effect of drug may relate 
primarily to blood pressure reduction, as suggested 
by Waters et al. in their study of nicardipine [8], and 
demonstrates that benefit can be extended to normo- 
tensive patients (SBP -> 100 -< 160 mmHg; DBP -< 95 
mmHg) even if blood pressure reductions are appar- 
ent. A similar rationale accounts for the requirement 
of normal LDL cholesterol levels [-<4.27 mmol/1 (165 
mg/dl)], since concomitant modification of this risk 
factor could ultimately confound a positive result. By 
allowing non-insulin-dependent diabetics to partici- 
pate in the study, we have the opportunity to evaluate 
the benefit of an ACE inhibitor in a population at im 
creased risk of cardiovascular disease and perhaps 
gain insight into the role of insulin resistance in the 
progression of coronary artery disease. 
Studies with angiographic endpoints [2-4,7,8] have 
shown that medical therapy can attenuate the rate 
of lesion development and/or reduce existing lesions. 
However, most angiographic studies have had too 
small a sample size to detect a reduction in morbidity 
or mortality associated with the measured changes in 
coronary artery diameter. The relatively large sample 
in QUIET accommodates both clinical and angio- 
graphic endpoints in defining efficacy. 
While not the first study to look at a spectrum of 
clinical sequelae, QUIET identifies varied endpoints 
as primary efficacy parameters, constructs a severity 
scale that recognizes multiple endpoints within one 
patient in the "time to event" analysis, and allows for 
different temporal sequences of events during the 
double-blind phase ("early" vs. "late" events). Since 
"early" events related to restenosis may represent dif- 
ferent pathophysiological processes than "late" 
events, such as atherosclerosis, plaque rupture, and 
thrombosis, it was necessary to power (albeit at 80%) 
the study for both phases. 
In summary, QUIET is the first study to address 
the long4erm effects of ACE inhibition on the natural 
history of coronary artery disease in a normolipidemic 
population without left ventricular dysfunction, both 
in terms of clinical endpoints and angiographically. In 
addition to insulin resistance, other substudies will 
examine endothelial reactivity and intracoronary ul- 
trasound evidence of plaque volume and restenosis. 
Enrollment in QUIET is complete and the trial is ex- 
pected to conclude by the end of January 1996. Evi- 
dence of reduction in the ischemic event rate could 
have important implications for the use of quinapril in 
both the secondary, and possibly the primary, preven- 
tion of cardiac disease. 
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